{"id":"memantine-twice-daily","safety":{"commonSideEffects":[{"rate":"5–10%","effect":"Dizziness"},{"rate":"5–10%","effect":"Headache"},{"rate":"5–10%","effect":"Constipation"},{"rate":"3–5%","effect":"Confusion"},{"rate":"2–4%","effect":"Hypertension"},{"rate":"2–3%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Memantine selectively blocks NMDA receptor channels in a use-dependent manner, reducing pathological calcium influx caused by chronic glutamate excitotoxicity while preserving normal synaptic transmission. This mechanism is thought to protect neurons from degeneration in neurodegenerative diseases, particularly Alzheimer's disease, by moderating overactive glutamatergic signaling without completely blocking physiological NMDA receptor function.","oneSentence":"Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks excessive glutamate signaling in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:20.774Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe Alzheimer's disease"},{"name":"Mild to moderate Alzheimer's disease (in combination with cholinesterase inhibitors)"}]},"trialDetails":[{"nctId":"NCT07470606","phase":"PHASE2","title":"Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-03","conditions":"Brain Tumor","enrollment":108},{"nctId":"NCT03553875","phase":"PHASE3","title":"Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2018-11-13","conditions":"Autism, Autism Spectrum Disorder, Nonverbal Learning Disability","enrollment":25},{"nctId":"NCT07248228","phase":"PHASE2","title":"Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)","status":"NOT_YET_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2026-03","conditions":"Brain Metastases","enrollment":90},{"nctId":"NCT03527472","phase":"PHASE2","title":"Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2018-08-23","conditions":"Lupus Erythematosus, Systemic","enrollment":111},{"nctId":"NCT05063851","phase":"PHASE2","title":"The Use of Memantine for Prevention of Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Virginia","startDate":"2021-10-11","conditions":"Alzheimer Disease","enrollment":32},{"nctId":"NCT03550391","phase":"PHASE3","title":"Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-11-22","conditions":"Brain Metastases","enrollment":206},{"nctId":"NCT02144584","phase":"EARLY_PHASE1","title":"Memantine for Enhanced Stroke Recovery","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2014-01","conditions":"Ischemic Stroke, Upper Extremity Weakness","enrollment":20},{"nctId":"NCT05564169","phase":"PHASE3","title":"Masitinib in Patients With Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"AB Science","startDate":"2026-06","conditions":"Alzheimer Disease","enrollment":600},{"nctId":"NCT04539951","phase":"PHASE2","title":"Pragmatic Trial of Obsessive-compulsive Disorder","status":"RECRUITING","sponsor":"Shanghai Mental Health Center","startDate":"2020-09-22","conditions":"Obsessive-Compulsive Disorder","enrollment":1600},{"nctId":"NCT05045950","phase":"PHASE2","title":"Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-11-17","conditions":"Brain Metastases","enrollment":53},{"nctId":"NCT06275035","phase":"PHASE3","title":"Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2024-02-22","conditions":"Neurocognitive Dysfunction","enrollment":101},{"nctId":"NCT06914310","phase":"PHASE2, PHASE3","title":"Memantine as an Additive Therapy in Patients With Traumatic Brain Injury","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2025-03-25","conditions":"Mild Traumatic Brain Injury, Moderate Traumatic Brain Injury (TBI)","enrollment":80},{"nctId":"NCT06594172","phase":"PHASE2","title":"Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2024-09-10","conditions":"Radiation Disease, Cognitive Impairment, Drug Effect","enrollment":67},{"nctId":"NCT01333865","phase":"PHASE4","title":"A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-01","conditions":"Autism Spectrum Disorders","enrollment":25},{"nctId":"NCT01972074","phase":"PHASE3","title":"Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2015-02-17","conditions":"Autism Spectrum Disorder","enrollment":84},{"nctId":"NCT01872598","phase":"PHASE3","title":"Masitinib in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"AB Science","startDate":"2012-01","conditions":"Alzheimer Disease","enrollment":721},{"nctId":"NCT02580305","phase":"PHASE2","title":"SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study","status":"COMPLETED","sponsor":"Suven Life Sciences Limited","startDate":"2015-09","conditions":"Alzheimer's Disease","enrollment":564},{"nctId":"NCT04033419","phase":"PHASE2","title":"Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-09-25","conditions":"Cognitive Decline, Chemo-brain","enrollment":55},{"nctId":"NCT05807165","phase":"","title":"HF-SRT vs. HS-WBRT in Treating Patients With Brain Oligometastases","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-08-01","conditions":"Brain Oligometastases","enrollment":115},{"nctId":"NCT02118727","phase":"PHASE2","title":"Therapy in Amyotrophic Lateral Sclerosis (TAME)","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-11-07","conditions":"Amyotrophic Lateral Sclerosis, Frontal Temporal Dementia","enrollment":89},{"nctId":"NCT05531383","phase":"NA","title":"Effect of Early Memantine Administration on Outcome of Patients With Moderate to Severe Traumatic Brain Injury","status":"UNKNOWN","sponsor":"Minia University","startDate":"2021-11-26","conditions":"Traumatic Brain Injury","enrollment":70},{"nctId":"NCT03986424","phase":"PHASE3","title":"Local Study of Akatinol Memantine in VaD in Russia","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2018-01-23","conditions":"Vascular Dementia","enrollment":130},{"nctId":"NCT05430867","phase":"PHASE4","title":"Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-07-01","conditions":"Treatment, Efficacy, Safety","enrollment":150},{"nctId":"NCT01535040","phase":"PHASE2","title":"Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2012-08-01","conditions":"Breast Cancer, Colorectal Cancer, Lung Cancer","enrollment":130},{"nctId":"NCT03221894","phase":"","title":"A Retrospective Study to Investigate the Additive Effectiveness of Chinese Herbal Medicine in Alzheimer's Disease","status":"COMPLETED","sponsor":"Dongzhimen Hospital, Beijing","startDate":"2017-07-15","conditions":"Alzheimer Disease","enrollment":120},{"nctId":"NCT03858270","phase":"PHASE3","title":"Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine","status":"UNKNOWN","sponsor":"Wayne State University","startDate":"2019-04-01","conditions":"Parkinson Disease","enrollment":50},{"nctId":"NCT03802162","phase":"PHASE1","title":"A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-02-15","conditions":"Alzheimer's Disease (AD)","enrollment":60},{"nctId":"NCT01902004","phase":"PHASE4","title":"Brain Aging and Treatment Response in Geriatric Depression","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2013-10","conditions":"Mild Cognitive Impairment (MCI), Depression","enrollment":115},{"nctId":"NCT00674219","phase":"PHASE3","title":"Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2005-05","conditions":"Obsessive-Compulsive Disorder, Generalized Anxiety Disorder","enrollment":17},{"nctId":"NCT01656187","phase":"PHASE4","title":"Attenuation of Corticosteroid Induced Hippocampal Changes","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2012-01","conditions":"Organic Memory Impairment","enrollment":46},{"nctId":"NCT02553928","phase":"PHASE4","title":"Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-10","conditions":"Alzheimer Dementia (AD)","enrollment":62},{"nctId":"NCT00136747","phase":"PHASE1","title":"The Effects of Memantine and Bupropion on Acute, Reinforcing, and Conditioned Effects of Cigarettes - 1","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2004-01","conditions":"Tobacco Use Disorder","enrollment":45},{"nctId":"NCT00183729","phase":"PHASE4","title":"Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults","status":"COMPLETED","sponsor":"Eric Lenze","startDate":"2005-08","conditions":"Depression","enrollment":35},{"nctId":"NCT00586066","phase":"PHASE4","title":"Memantine and Cognitive Dysfunction in Bipolar Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2005-11","conditions":"Bipolar Disorder","enrollment":72},{"nctId":"NCT00294554","phase":"NA","title":"Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2006-04","conditions":"Parkinson's Disease, Cognitive Impairment, Dementia","enrollment":20},{"nctId":"NCT00566852","phase":"PHASE3","title":"Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-03","conditions":"Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity","enrollment":554},{"nctId":"NCT01054599","phase":"NA","title":"Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?","status":"COMPLETED","sponsor":"American Academy of Neurology","startDate":"2009-01","conditions":"Epilepsy","enrollment":29},{"nctId":"NCT00264238","phase":"PHASE1, PHASE2","title":"Memantine Augmentation in Obsessive-Compulsive Disorder","status":"COMPLETED","sponsor":"Stanford University","startDate":"2006-01","conditions":"Obsessive-Compulsive Disorder","enrollment":15},{"nctId":"NCT00986115","phase":"NA","title":"Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy","status":"WITHDRAWN","sponsor":"University of California, Davis","startDate":"2010-07","conditions":"Epilepsy","enrollment":""},{"nctId":"NCT00462228","phase":"PHASE4","title":"Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury","status":"TERMINATED","sponsor":"University of Missouri-Columbia","startDate":"2007-04","conditions":"Traumatic Brain Injury","enrollment":11},{"nctId":"NCT00120874","phase":"PHASE4","title":"Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2006-08","conditions":"Alzheimer's Disease","enrollment":20},{"nctId":"NCT00928954","phase":"NA","title":"Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus","status":"COMPLETED","sponsor":"Case Western Reserve University","startDate":"2005-02","conditions":"Nystagmus","enrollment":10},{"nctId":"NCT01260467","phase":"PHASE2","title":"Memantine for Recurrent Glioblastoma","status":"TERMINATED","sponsor":"University of Rochester","startDate":"2010-11","conditions":"Glioblastoma","enrollment":4},{"nctId":"NCT00630500","phase":"PHASE2","title":"Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)","status":"COMPLETED","sponsor":"Helse Stavanger HF","startDate":"2006-02","conditions":"Dementia Associated With Parkinson's Disease, Dementia With Lewy Bodies","enrollment":75},{"nctId":"NCT01052662","phase":"PHASE2, PHASE3","title":"Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2009-10","conditions":"Opioid Dependence","enrollment":87},{"nctId":"NCT00235716","phase":"PHASE3","title":"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2007-08","conditions":"Alzheimer's Disease","enrollment":613},{"nctId":"NCT01626391","phase":"PHASE2","title":"Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease","status":"TERMINATED","sponsor":"TauRx Therapeutics Ltd","startDate":"2012-09","conditions":"Alzheimer's Disease","enrollment":9},{"nctId":"NCT01844427","phase":"NA","title":"Memantine Monotherapy for Executive Dysfunction and ADHD","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2013-07","conditions":"ADHD, Executive Function Deficits (EFD's)","enrollment":""},{"nctId":"NCT00862940","phase":"PHASE4","title":"A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2005-09","conditions":"Alzheimer's Disease","enrollment":277},{"nctId":"NCT00586573","phase":"PHASE4","title":"Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2007-03","conditions":"ADHD","enrollment":34},{"nctId":"NCT00649220","phase":"PHASE4","title":"Memantine and Antipsychotics Use","status":"TERMINATED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2008-07","conditions":"Alzheimer's Disease","enrollment":19},{"nctId":"NCT01041313","phase":"PHASE4","title":"Memantine for Post-Operative Pain Control","status":"UNKNOWN","sponsor":"University of Washington","startDate":"2010-01","conditions":"Pain, Post-operative","enrollment":120},{"nctId":"NCT00469456","phase":"PHASE4","title":"Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2007-04","conditions":"Alzheimer's Disease","enrollment":265},{"nctId":"NCT00757978","phase":"PHASE4","title":"Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2006-01","conditions":"Schizophrenia","enrollment":22},{"nctId":"NCT00640198","phase":"PHASE4","title":"Memantine and Intensive Speech-Language Therapy in Aphasia","status":"COMPLETED","sponsor":"Gabinete Berthier y Martínez","startDate":"2005-03","conditions":"Aphasia, Stroke","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":59,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lu 00-800","Ebixa ®","Ebix ®"],"phase":"marketed","status":"active","brandName":"Memantine (twice daily)","genericName":"Memantine (twice daily)","companyName":"H. Lundbeck A/S","companyId":"h-lundbeck-a-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks excessive glutamate signaling in the brain. Used for Moderate to severe Alzheimer's disease, Mild to moderate Alzheimer's disease (in combination with cholinesterase inhibitors).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}